ChiCTR2500115050 版本V1.0 版本创建时间2025/12/22 10:34:34 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500115050 

最近更新日期:

Date of Last Refreshed on:

2025-12-22 10:34:27 

注册时间:

Date of Registration:

2025-12-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

碘伏消毒凝胶用于治疗创面感染的安全性与有效性的前瞻性研究

Public title:

A prospective study evaluating the safety and efficacy of povidone-iodine disinfectant hydrogel for the treatment of wound infections

注册题目简写:

English Acronym:

研究课题的正式科学名称:

碘伏消毒凝胶用于治疗创面感染的安全性与有效性的前瞻性研究

Scientific title:

A prospective study evaluating the safety and efficacy of povidone-iodine disinfectant hydrogel for the treatment of wound infections

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨梦蝶 

研究负责人:

蔡蕴敏 

Applicant:

Mengdie Yang 

Study leader:

Yunmin Cai 

申请注册联系人电话:

Applicant telephone:

+86 152 5654 5014

研究负责人电话:

Study leader's telephone:

+86 189 3081 9161

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

mdyang@linglecn.com

研究负责人电子邮件:

Study leader's E-mail:

cymajj@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国广东省中山市翠亨新区未来大道50号GMP厂房2栋2层

研究负责人通讯地址:

中国上海市金山区龙航路1508号

Applicant address:

Building 2, Floor 2, GMP Factory, No. 50, Futian Road, Cuiheng New District, Zhongshan, Guangdong, China

Study leader's address:

No. 1508 Longhang Road, Jinshan District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

528400

研究负责人邮政编码:

Study leader's postcode:

528400

申请人所在单位:

中山光禾医疗科技有限公司

Applicant's institution:

ZhongShan Guanghe Medical Technology Co., Ltd.

研究负责人所在单位:

复旦大学附属金山医院

Affiliation of the Leader:

Jinshan Hospital of Fudan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

JIEC 2025-S75

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属金山医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Jinshan Hospital of Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-25 00:00:00

伦理委员会联系人:

王淑颖

Contact Name of the ethic committee:

Shuying Wang

伦理委员会联系地址:

中国上海市金山区龙航路1508号

Contact Address of the ethic committee:

No. 1508 Longhang Road, Jinshan District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 57039818

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属金山医院

Primary sponsor:

Jinshan Hospital of Fudan University

研究实施负责(组长)单位地址:

中国上海市金山区龙航路1508号

Primary sponsor's address:

No. 1508 Longhang Road, Jinshan District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属金山医院

具体地址:

中国上海市金山区龙航路1508号

Institution
hospital:

Jinshan Hospital of Fudan University

Address:

No. 1508 Longhang Road, Jinshan District, Shanghai, China

经费或物资来源:

中山光禾医疗科技有限公司

Source(s) of funding:

ZhongShan Guanghe Medical Technology Co., Ltd.

Target disease:

Wound infection

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

通过将碘伏消毒凝胶用于感染创面,评价使用7天后,该产品用于治疗创面感染的有效率  

Objectives of Study:

By applying povidone-iodine disinfectant hydrogel to infected wounds, evaluate the effectiveness rate of this product in treating wound infections after 7 days of use.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.自愿参与研究并签署了书面知情同意书的受试者; 2.性别不限,签署知情同意书时年龄在18-85周岁(含边界值); 3.位于肢体或躯干部位、面积2cm2-100cm2,累及皮肤或皮下组织的创面感染,包括烧伤创面、外伤性溃疡、压疮、静脉性溃疡或糖尿病性溃疡感染等; 4.接受细菌学样本采集,经镜检为阳性者; 5.创面感染临床表现至少2项:局部脓液或炎性渗出物,恶臭,创周皮肤红斑,组织肿胀或硬结,创周皮肤发热,局部疼痛或触痛。

Inclusion criteria

1.Subjects who voluntarily participate in the study and have signed a written informed consent form; 2.No gender restriction; subjects must be aged 18 to 85 years (inclusive) at the time of signing the informed consent form. 3.Wound infections located on the extremities or trunk, with an area of 4-100 cm2, involving the skin or subcutaneous tissue. These include infections of burn wounds, traumatic ulcers, pressure ulcers, venous ulcers, or diabetic ulcers, etc. 4.Subjects who have undergone bacteriological sample collection and tested positive by microscopic examination; 5.At least 2 of the following clinical manifestations of wound infection: local pus or inflammatory exudate, foul odor, erythema of the skin around the wound, tissue swelling or induration, warmth of the skin around the wound, local pain or tenderness.

排除标准:

1.处于妊娠期或者哺乳期的女性; 2.感染/坏死累及深筋膜、肌肉等深层软组织,或形成深在窦道或面部; 3.入组前未做细菌培养者; 4.全身感染表现明显,或全身病情较重,需要系统用药或手术干预; 5.既往肿瘤病史或需使用免疫抑制剂者; 6.有严重心血管系统、肝脏、肾脏或血液系统疾病者; 7.有精神分裂症病史或其他严重精神疾病史、药物或酒精滥用; 8.已知对本产品过敏的受试者; 9.最近3个月参加过其他临床试验; 10.研究者认为研究期间不能遵循方案要求完成研究的受试者; 11. 研究者认为受试者不适合参与本研究的任何情况

Exclusion criteria:

1.Women who are pregnant or lactating; 2.Infection/necrosis involves deep soft tissues such as the deep fascia and muscles, or forms a deep sinus tract,or face; 3.Subjects who did not undergo bacterial culture before enrollment; 4.Subjects with obvious manifestations of systemic infection, or those with severe systemic conditions that require systemic medication or surgical intervention; 5.Subjects with a history of previous tumors or those who require the use of immunosuppressants; 6.Subjects with severe diseases of the cardiovascular system, liver, kidneys, or hematological system; 7.Subjects with a history of schizophrenia, a history of other severe mental illnesses, or a history of drug or alcohol abuse 8.Subjects with a known allergy to this product; 9.Subjects who have participated in other clinical trials within the recent 3 months; 10.Subjects whom the investigator deems unable to comply with the protocol requirements to complete the study during the study period; 11.Researchers consider any situation in which the participants are not suitable for participating in this study

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-01 00:00:00 To 2026-07-01 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

20

Group:

Experimental group

Sample size:

干预措施:

碘伏消毒凝胶

干预措施代码:

Intervention:

Povidone-iodine disinfectant hydrogel

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属金山医院 

单位级别:

三甲 

Institution
hospital:

Jinshan Hospital of Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

治疗后第7天创面感染治疗的有效率

指标类型:

主要指标

Outcome:

The effective rate of wound infection treatment on the 7th day after treatment

Type:

Primary indicator

测量时间点:

治疗后第7天

测量方法:

Measure time point of outcome:

On the 7th day after treatment

Measure method:

指标中文名:

治疗后7天创面愈合率

指标类型:

次要指标

Outcome:

Wound healing rate 7 days after treatment

Type:

Secondary indicator

测量时间点:

治疗后第7天

测量方法:

Measure time point of outcome:

On the 7th day after treatment

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

创面的细菌标本

组织:

Sample Name:

Bacterial specimen from the wound

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-12-22 10:34:27